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Summary 
Rhodococcus equi (R. equi) is an important pulmonary pathogen in foals that 
often leads to the death of the horse. The bacterium harbours a virulence 
plasmid that encodes numerous virulence associated proteins (Vaps) 
including VapA that is essential for intracellular survival inside macrophages. 
However, little is known about the precise function of VapA. Here we 
demonstrate that VapA causes perturbation to late endocytic organelles with 
swollen endolysosome organelles having reduced cathepsin-B activity and an 
accumulation of LBPA, LC3 and Rab7. The data are indicative of a loss of 
endolysosomal function, which leads cells to up-regulate lysosome biogenesis 
to compensate. Although there is a high degree of homology of the core 
region of VapA to other Vap proteins, only the highly conserved core region of 
VapA, and not VapD of VapG, gives the observed effects on endolysosomes. 
This is the first demonstration of how VapA is working and implies that VapA 
aids R. equi survival by reducing the impact of lysosomes on phagocytosed 
bacteria. 
 
  
Introduction 
Rhodococcus equi, (R. equi) is a Gram-positive facultative intracellular 
pathogen with similarities to Mycobacterium tuberculosis (Vazquez-Boland et 
al., 2013). Pathogenic R. equi infects a wide variety of animal hosts including 
pigs, sheep and cattle, but is most frequently associated with 
bronchopneumonial disease in foals and is increasingly isolated from 
immunocompromised humans (Topino et al., 2010, Hayes et al., 2011, Khan 
et al., 2013, Nath et al., 2013). Transmission of infection in foals is thought to 
occur through inhalation of contaminated dust or soil particles (Muscatello et 
al., 2006). R. equi represents a major threat to foal health worldwide and has 
a significant economic impact on the horse breeding industry. Current 
treatments for R. equi infections involve combination drug therapies with 
rifampin and macrolides such as clarithromycin (Giguère et al., 2011). These 
treatments can be protracted and expensive, and are not always successful. 
Furthermore, antibiotic resistant strains are emerging (Burton AJ et al., 2013). 
While promising potential vaccines are in development, there are still no 
commercially-available vaccines (Cauchard S et al., 2013) and research 
efforts are now focussing on the mechanisms of pathogenicity induced by R. 
equi in order to provide insights which may lead to better treatments for 
infection. 
 
R.equi is phagocytosed by lung alveolar macrophages and becomes enclosed 
in an internal vacuole called the R.equi-containing vacuole (RCV) in which the 
bacterium survives. The precise character of this vacuolar compartment is 
unclear since there are conflicting reports on whether R. equi reaches the 
degradative environment of the lysosome (Fernandez-Mora et al., 2005, 
Toyooka et al., 2005). It is therefore uncertain how R.equi is able to survive 
intracellularly. Eventually R. equi begins to multiply within the RCV, resulting 
in necrosis of the host cell (Luhrmann et al., 2004).  
 
The ability of R.equi to persist and replicate intracellularly is dependent upon 
the presence of a ~ 90 kb virulence plasmid, which plays a crucial role in 
intracellular survival. Loss of the virulence plasmid renders the bacteria 
unable to replicate inside macrophages in vitro (Hondalus et al., 1994, 
Giguere et al., 1999). Avirulent strains are also cleared significantly faster in a 
mouse lung infection model than strains harbouring this extra chromosomal 
element (Gonzalez-Iglesias et al., 2014). A striking feature of the virulence 
plasmid is the presence of a pathogenicity island containing several genes 
encoding virulence-associated proteins (Vaps). The expression of one of 
these genes in particular, VapA, has been associated with virulence in vivo in 
both mice and foals (Takai et al., 1991, Giguere et al., 1999). VapA has also 
been shown to be necessary, but not sufficient for virulence, since VapA 
alone can restore virulence to a Vap-A, -C, -D, -E and -F deletion mutant (Jain 
et al., 2003) but cannot restore virulence to plasmid-cured R. equi strains 
(Giguere et al., 1999). More recently, it has been shown that vapA along with 
two other genes virR and virS, are the minimum genes required to confer 
virulence, in the absence of the virulence plasmid (Coulson et al., 2015). VirR 
is a LysR-type transcriptional regulator (Russell et al., 2004) and VirS is an 
OmpR/PhoB response regulator (Kakuda et al., 2014), both of which are 
required for proper vapA gene expression (Ren et al., 2004). The presence of 
VirR and VirS alters transcription of ~18 % of R. equi genes. This suggests 
that the plasmid is also needed to regulate chromosomal genes that may be 
required for intracellular growth (Coulson et al., 2015). VapA has also been 
demonstrated to be necessary to reduce fusion of R. equi containing 
phagosomes with lysosomes (Fernandez-Mora et al., 2005, von Bargen et al., 
2009). 
Sequence alignment of the different Vap proteins shows that they share a 
high degree of homology in the C-terminus with little homology in the N-
terminus of the proteins. The crystal structures of VapB, VapD and VapG 
have been determined by X-ray crystallography (Geerds et al., 2014, 
Whittingham et al., 2014, Okoko et al., 2015) revealing that the highly 
conserved C-terminal region forms a tightly packed eight-stranded β-barrel 
and that the structures of these Vap proteins are superimposable. However, 
the crystal structures of the Vap proteins don’t show any obvious ligand 
binding sites or grooves that would provide clues to their function.  It is 
predicted, by homology, that VapA will have a similar structure to other Vap 
proteins yet there is nothing obvious in the VapA sequence that indicates why 
VapA is unique among the Vap proteins in being necessary for virulence.  
Given the importance of VapA for R.equi intracellular survival we sought to 
determine how VapA alone affects the endocytic pathway. Our data indicate 
that only the β-barrel structure of VapA and not the β-barrel structure of other 
Vap proteins disrupts endolysosome function, promoting cells to up-regulate 
lysosome biogenesis to compensate for the loss of functional endolysosomes. 
Whilst VapA has been shown to be important for virulence, these are the first 
data that demonstrate that VapA could aid R. equi intracellular survival by 
reducing cellular lysosomal function.  
Results 
VapA causes swelling of late endocytic compartments 
VapA is the only Vap gene that is essential for virulence (Jain et al., 2003) yet 
its molecular function remains unknown. Normally, phagocytosis of bacteria 
results in the delivery of the bacteria to lysosomes where they are destroyed 
by lysosomal acid hydrolases and indeed VapA has been shown to reduce 
fusion of the R. equi containing phagosome with lysosomes (Fernandez-Mora 
et al., 2005). However, we wanted to test the hypothesis that VapA may 
disrupt lysosomal function per se thereby allowing R. equi to survive 
intracellularly. We first expressed myc-tagged VapA (under the control of a 
doxycycline inducible promoter) for 24 h in the cytoplasm of HeLa cells and 
the morphology of endocytic compartments was determined by confocal 
microscopy (Fig. 1). EEA1, ciMPR and LAMP1 staining (markers of early 
endosomes, late endosomes and lysosomes respectively) in cells expressing 
myc-VapA were indistinguishable from that seen in control cells. Given that 
R.equi has no known secretory system for translocating effector proteins into 
the host cell cytoplasm (Letek et al., 2010) we also considered the possibility 
that VapA may aid R.equi survival from within the R.equi-containing vacuole 
(RCV). To test this hypothesis, VapA was produced recombinantly with either 
an N-terminal GST tag or a C-terminal His6 tag.  HeLa cells, J774.2 mouse 
macrophages and Normal Rat Kidney (NRK) cells were incubated with 100 
µg/ml tagged-VapA, to allow VapA to be taken up by fluid-phase endocytosis. 
Strikingly, the late endosomes (Fig. S1) and lysosomes in these cells became 
enlarged and swollen (Fig. 2A,B), whereas early endocytic compartments 
(EEA1 positive puncta) were not affected (Fig. S1). This swollen lysosomal 
phenotype was not caused by LPS endotoxin (that might be present in the 
VapA protein preparation) or the GST tag, as GST and LPS endotoxin had no 
effect on lysosome morphology (Fig. 2C). Therefore the swollen lysosomal 
phenotype was due to the presence of VapA. Typically, over 65% of all HeLa 
cells treated with VapA showed swollen lysosomes (Fig. 2D) with a 1.8-fold, a 
3-fold and a 4-fold increase in lysosomal size in HeLa, J774.2 and NRK cells 
respectively (Fig. 2E). Thus, we aimed to characterise the effect on late 
endosomes and lysosomes further. R. equi readily infects J774.2 cells (Fig. 
3A, Fig. S3) with a loss of discrete lysosomes (compared to uninfected cells), 
as has previously been reported (Hietala et al., 1987, Zink et al., 1987, von 
Bargen et al., 2009). Although macrophages are the normal host cell for R. 
equi, the available cell line (J774.2) is not ideal for confocal analysis since all 
endocytic compartments are in close proximity, which hinders their analyses. 
Due to the spatial distribution of lysosomes in NRK cells and the greatest 
differences in the size of lysosomes when fed VapA we used NRK cells for 
subsequent studies. Whilst NRK cells do not normally phagocytose bacteria, 
they can be infected with R. equi (Fig. 3B, Fig. S3). NRK cells are infected by 
R. equi with low efficiency compared to J774.2 cells (Fig. S3). However, the 
bacteria are able to replicate inside NRK cells as shown by Fig. 3B, since as 
the Alexa-Fluor-488-labelled bacteria replicate the surface fluorescence is lost 
but DAPI staining of nucleic acid of replicated bacteria can be seen. At 24h 
NRK cells show less lysis when infected with R. equi, compared to mouse 
macrophages, with no discernable loss of lysosomes, but it is unclear as to 
whether this is a difference in the cell type or that NRK cells aren’t as 
permissive for R. equi infection. However, infected NRK cells show swollen 
lysosomes, as visualized by LGP120 (rat equivalent of human LAMP1) 
immunofluorescence, (Fig. 3B) mirroring the phenotype seen when VapA 
protein is fed to NRK, J774.2 and HeLa cells. 
 
The core of VapA is sufficient to cause late endosome/lysosome swelling 
Whilst the amino acid sequences of the N-terminal segment of the Vap 
proteins do not share a high degree of homology and are not predicted to 
have any tertiary structure, the remaining part of the Vap proteins (C-terminal 
core structure) are remarkably conserved (Fig. 4 A).  Given the high degree of 
homology between the C-terminal core region of VapA and other Vap proteins 
(Whittingham et al., 2014) and their identical tertiary structures (Fig. 4B), we 
asked whether VapD or VapG were able to induce a similar phenotype to that 
seen with VapA. When NRK cells were incubated with VapD-His6 or VapG-
His6, no swelling of lysosomal compartments was observed compared to 
VapA (Fig. 4C). Since the major difference between the Vap proteins is in the 
N-terminal segment, we hypothesised that the N-terminal region of VapA 
would be responsible for the observed lysosomal swelling. We therefore 
sought to determine whether the N-terminus of VapA was necessary to induce 
the swollen lysosomal phenotype, or whether the N-terminus of other Vap 
proteins was inhibitory to any potential function of their C-terminal core region. 
NRK cells were incubated with VapA lacking the N-terminal segment (VapA 
core) or chimeric VapA/VapD proteins (Fig. 4D). After feeding cells 
recombinant proteins for 24 h, the morphology of late endosomes and 
lysosomes was examined. Cells incubated either the VapA core protein or a 
VapD (N-terminal segment)-VapA core chimeric protein had enlarged late 
endosomes and lysosomes. Conversely, the late endosomes and lysosomes 
of cells incubated with VapA (N-terminal region)-VapD core protein were 
identical to control cells. Thus, the N-terminal segment of VapA is not 
necessary for its activity and the core of VapA alone is sufficient to induce the 
swelling of endocytic compartments. This result was unexpected given the 
high degree of homology of the core region of VapA to the other Vap proteins. 
VapA induced swollen compartments accumulate intralumenal vesicles, LBPA 
Rab7 and LC3 
To understand further the nature of the swollen lysosomal compartment, NRK 
cells were pulse-chased with 10nm BSA-gold and the cells fixed for 
conventional electron microscopy. Electron micrographs of control cells show 
the BSA-gold in electron dense structures that have previously been 
characterized as lysosomes (Bright et al., 1997) (Fig. 5A). In cells fed VapA 
protein, the BSA-gold was found in large electron lucent structures (up to 1µm 
across) containing numerous intralumenal vesicles (Fig. 5A). The fusion of a 
lysosome with a late endosome forms an endolysosome (EL) and these data 
suggested that VapA might be interfering with the EL, trapping material in an 
endolysosomal-like compartment and thus preventing lysosome re-formation. 
To test this hypothesis we fractionated NRK cells on a Nycodenz gradient and 
showed that 24h after feeding cells VapA, the lysosomal acid hydrolase ß-
hexosaminidase partially shifted to a less-dense region of the gradient (Fig. 
5B). At longer time points (48h) this shift in density was not observed, which 
corresponds with a diminished swollen phenotype seen at this time (see later, 
Fig. 7). If VapA was trapping material in an EL then we might have observed 
the late-endosomal marker ciMPR co-migrating with the pool of less-dense ß-
hexosaminidase-positive material at 24h. However, the converse was 
observed and the ciMPR was seen to migrate to a denser part of the gradient 
(Fig. 5C). This is consistent with immunofluorescence data where we don’t 
see an increase in the co-localisation between late endosomes and 
lysosomes in the presence of VapA (Fig. 4E). However, we cannot rule out 
that the ciMPR can be retrieved from the swollen compartments. The idea that 
there is still membrane flow out of these swollen structures is confirmed by the 
observation that there was no cholesterol accumulation (as assessed by filipin 
staining) in these compartments (Fig. 5D). Further characterization of the 
swollen structures showed that there was an increase in the co-localisation 
between lysosomes (labeled with LGP110, the rat equivalent of human 
LAMP2) and the late-endosomal unconventional phospholipid 
lysobisphosphatidic acid (LBPA) (Fig. 5E, Fig. S5). The swollen 
compartments were also tightly associated with the late endosomal Rab 
protein Rab7, with very little Rab7 seen in the cytoplasm compared to control 
cells (Fig. 5F, Fig. S5). Consistent with earlier EEA1 data (Fig. S1), there 
wasn’t any visible effect on the early-endosomal Rab protein Rab 5 (Fig. 5G) 
although the extent of colocalisation between Rab5 and LGP120 was found to 
increase (Fig. S5). The most dramatic effect was seen with the 
autophagosomal marker LC3. LC3 becomes lipidated as it associates with the 
lumenal side of the developing autophagosomal membrane and it eventually 
gets delivered to the lysosome upon autolysosome formation where it gets 
degraded. In cells fed VapA there is an accumulation of LC3-positive puncta 
(Fig. 5H, Fig. S5) and these puncta are within the swollen LGP110 positive 
structures. Western blotting showed that VapA fed cells had a large increase 
in the lipidated form of LC3 (LC3-II; Fig. 5I). To determine whether the 
increase in LC3-II was due to an up-regulation of autophagy or a lack of LC3-
II clearance cells were also treated with Bafilomycin-A1, an inhibitor of the 
lysosomal V-ATPase. Bafilomycin treatment of cells did not further increase 
the levels of LC3-II (Fig. 5I) indicating that the increase in LC3-II was due to a 
lack of clearance and not an upregulation of autophagy. Together the 
accumulation of intralumenal vesicles, LBPA, Rab7 and LC3 in a LGP120/110 
positive compartment were consistent with there being a defect in ELs. 
Endolysosomes show reduced cathepsin-B activity in the presence of VapA 
The LC3 result suggests that there is a defect in the hydrolase activity in the 
swollen EL compartments. Whilst we have not directly measured the pH of 
these swollen compartments, the swollen compartments still accumulate 
LysoTracker, indicating that the swollen ELs are at least acidic (LysoTracker 
accumulates in compartments where the pH <6.5) (Fig. 6A). Indeed, in control 
cells and cells fed VapD there are lysosomes that are not labeled with 
LysoTracker, but in cells fed VapA there are very few LGP120 positive 
structures that are not labeled by LysoTracker (Fig. 6A), again indicating the 
loss of regular lysosomes in VapA fed cells. Whether there are any subtle 
changes in the pH of the ELs compared to control cells is difficult to measure 
since in control cells there would be few ELs, we therefore assessed the 
hydrolase activity in cells fed VapA using the Magic Red-Cathepsin B 
substrate (MRCBS), which is a substrate for cathepsin B that becomes 
fluorescent upon cathepsin B cleavage (Pryor, 2012). In control cells and cells 
fed VapA or VapD there was a good MRCBS signal, with the MRCBS seen in 
aggregated structures in VapA fed cells (Fig. 6B). We then performed 
fluorescence recovery after photobleaching (FRAP) experiments in control 
and VapA fed cells (Fig. 6C). In VapA fed cells there is a 35% reduction in the 
rate of recovery of MRCBS fluorescence after photobleaching, indicating a 
reduction in cathepsin-B activity (Fig. 6D). If other acid hydrolases also show 
this reduced hydrolytic activity then this could explain the accumulation of 
LBPA, Rab7 and LC3 and a swollen phenotype akin to a lysosomal storage 
disorder where material delivered to the lysosome is undigested. 
 
VapA induces lysosome biogenesis 
When NRK cells were incubated with VapA over a longer time course it was 
observed that there were more LGP120-positive puncta between 48 h and 
72h (Fig. 7A). Lysosome biogenesis is known to be upregulated in response 
to lysosomal dysfunction (Sardiello et al., 2009), which causes translocation of 
the transcription factor EB (TFEB) from the cytoplasm to the nucleus, resulting 
in a coordinated increase in expression of lysosomal genes. We hypothesised 
that the swollen ELs, induced by VapA, with reduced hydrolase activity would 
accumulate undigested material and this would result in an increase in 
lysosome biogenesis. NRK cells were incubated with VapA, VapD or VapG at 
100 µg/ml for 8 -72 h and the resultant lysates probed by western blotting for 
markers of late endosomes and lysosomes (Fig. 7B). The amount LGP120, a 
marker of lysosomes, increased in accordance with the time cells were 
incubated with VapA protein. Unlike LGP120 the amount of ciMPR, a marker 
of late-endosomes, did not increase. Cells incubated with VapD or VapG did 
not show an increase in levels of LGP120.  
We utilised a quantitative cytoplasm-to-nucleus translocation algorithm 
developed by Cellomics (Williams et al., 2006) to measure the translocation of 
GFP- tagged TFEB into the nucleus in response to lysosomal dysfunction. 
NRK cells stably expressing TFEB-GFP were incubated with 100 µg/ml VapA 
for 8 h or 24 h. After fixing the cells, the quantitative localisation of TFEB-GFP 
was determined with the Cellomics ArrayScanTM widefield microscopy system 
and the morphology of lysosomes was analysed by confocal microscopy (Fig. 
7C). After 8 h of incubation with VapA, some of the TFEB-GFP was observed 
to have translocated to the nucleus and swollen lysosomes could be seen. 
After 24 h most of the TFEB-GFP had translocated to the nucleus and the 
severity of the lysosomal phenotype had increased, as judged by an increase 
in the size of lysosomal puncta. No translocation of TFEB-GFP into the 
nucleus was seen in untreated control cells. In cells treated for 90 min with 
250 nM Torin 1 (a potent inhibitor of the mTOR complex, which is known to 
cause TFEB translocation into the nucleus), the majority of the TFEB-GFP 
had translocated to the nucleus. TFEB-GFP expressing NRK cells were 
incubated with increasing amounts of VapA, VapD or VapG recombinant 
protein. VapA induced the translocation of TFEB-GFP to the nucleus and this 
was in a dose-dependent manner (Fig. 7D). However neither VapD nor VapG 
had any effect on TFEB. Translocation of TFEB-GFP into the nucleus was 
also monitored over a longer time course (Fig. 7E). In cells treated with VapA 
there was an increase in the amount of nuclear TFEB-GFP by 8 h with 
nuclear translocation being maximal at 16 to 24 h. Neither VapD nor VapG 
induced the translocation of TFEB into the nucleus at any time point, relative 
to untreated control cells. Together these results suggest that VapA causes 
EL dysfunction and to compensate for the loss of lysosomes the cell up-
regulates lysosome biogenesis. 
 
Discussion 
The presence of the virulence plasmid in R. equi is widely accepted as a 
prerequisite for intracellular survival and replication inside eukaryotic cells 
(Hondalus et al., 1994). The expression of VapA in particular has been 
associated with virulence in vivo in both mice and foals (Giguere et al., 1999). 
Despite the importance of VapA in R. equi pathogenesis, little is known about 
its molecular function although it is has been reported to reduce fusion of R. 
equi phagosomes with the lysosome (Fernandez-Mora et al., 2005, von 
Bargen et al., 2009) but how is unclear. A successful intracellular pathogen is 
often one that can avoid, or survive being delivered to, the hydrolytic 
environment of the lysosome. We therefore sought to determine whether 
VapA disrupted the lysosome itself, as a potential mechanism for allowing 
R.equi to survive intracellularly. 
Some intracellular pathogens harbour type three secretion systems (T3SS), 
which translocate effector proteins across host-cell membranes. While R.equi 
possesses a type seven secretion system (T7SS) that allows proteins to be 
secreted into the RCV, there is no identified T3SS in R. equi to secrete 
proteins into the host cell’s cytoplasm. In this respect, R. equi is similar to 
Mycobacterium tuberculosis, which also lacks a known T3SS, even though 
effector proteins such as SapM, PtpA and PtpB are known to act on 
cytoplasmic lipids and/or proteins (Saleh et al., 2000, Mascarello et al., 2013, 
Margenat et al., 2015).  Given that VapA expression in the cytoplasm of HeLa 
cells did not cause any morphological changes to endocytic compartments, 
we hypothesised that the RCV represents the site of VapA activity. To test 
this, we cultured cells in the presence of recombinant Vap proteins, resulting 
in their uptake into endocytic compartments through fluid-phase endocytosis. 
We confirmed that recombinant protein accumulated in endocytic 
compartments (Fig. 2) and that VapA isn’t just signaling through cell surface 
receptors. Importantly, we observed in a variety of cell types that when cells 
were fed recombinant VapA, the late endosomes/lysosomes rapidly became 
enlarged. Characterising this phenotype further we see large structures with 
intralumenal vesicles that are reminiscent of endolysosomes, with an 
accumulation of the late endocytic markers LBPA and Rab7 and reduced 
clearance of the autophagy marker LC3. These VapA-induced swollen EL 
compartments are still acidic, though we cannot rule out that the pH has 
changed, and have reduced cathepsin-B activity. The enlarged lysosome 
phenotype is similar to the lysosome phenotype in cells that have a lysosome 
storage disorder and accumulate undigested substrates. Lysosome 
dysfunction results in upregulation of lysosome biogenesis coordinated via the 
transcription factor EB (TFEB) (Sardiello et al., 2009, Settembre et al., 2012). 
We found that VapA caused lysosomal biogenesis as assessed by 
translocation of TFEB into the cell nucleus and western blotting for the 
lysosomal marker LGP120 in rat cells. The up-regulation of lysosome 
biogenesis is a consequence of lysosome disruption. In our system 
lysosomes would be lost as they become consumed in the formation of 
perturbed endolysosomes. This is consistent with the loss of lysosomes seen 
in R. equi infected cells (Hietala et al., 1987, Zink et al., 1987). However, we 
then see lysosome biogenesis, which indicates a loss of lysosome function.  
Lysosome biogenesis is not seen in R. equi infected macrophages since the 
macrophages undergo necrosis first, in a VapA-independent manner (von 
Bargen et al., 2009). But we do see lysosome biogenesis in J774.2 cells when 
fed VapA alone (data not shown).  
By disrupting endolysosome function, which is essentially the phagolysosomal 
compartment, VapA can reduce the impact of lysosomal hydrolases and 
therefore can create an intracellular niche that aids R. equi survival. It is 
possible that R. equi phagosomes do indeed fuse with a few lysosomes, but 
eventually the phagolysosome becomes non-fusogenic to further lysosomal 
fusion, which would show up as an overall lack of delivery to many 
lysosomes. Our studies have only examined the role of VapA, since it is 
essential for virulence, but this does not preclude other factors that may aid R. 
equi virulence. For instance, similar to M.tuberculosis, R.equi has a 
hydrophobic cell wall containing unusual mycolic acid-containing glycolipids 
such as trehalose dimycolate and lipoarabinomannan (Alvarez, 2010). It has 
been shown that mannose-capped lipoarabinomannan disrupts traffic 
between the trans Golgi network and the M.tuberculosis phagosome, resulting 
in the exclusion of the vATPase (Fratti et al., 2003). These lipids may play a 
similar role in altering the acidification of the RCV.  
 
Our data show that VapA perturbs endolysosomes and we therefore suggest 
that the physiologically altered ELs are unable to digest lumenal material and 
subsequently the compartment does not condense to re-form lysosomes. The 
net result is an accumulation of undigested material and a loss of terminal 
lysosomes as they become consumed into the ELs. The loss of lysosomes 
and lysosomal function is sensed by the cell resulting in TFEB translocation to 
the nucleus and an increase in lysosome biogenesis (Fig. 8). 
 
Due to the close homology in the Vaps in both sequence and structure, we 
considered the possibility that other Vap proteins may be able to induce the 
same effects as VapA. Interestingly, when NRK cells were incubated with 
either VapD or VapG, no changes to lysosome morphology were seen and 
lysosomal staining was indistinguishable from that of control cells. Although it 
is possible that the other Vap proteins act synergistically or are somehow 
modified or regulated by the activity of VapA, we found that when cells were 
incubated with VapD and VapG in combination, they had no effect on 
lysosomes (data not shown). It therefore remains unclear what the function of 
these additional Vaps is, considering that expression of these proteins is 
induced during intracellular growth (Byrne et al., 2001, Ren et al., 2003) and 
under the low pH conditions encountered in the macrophage phagosome, 
(Benoit et al., 2001).  
 
We also investigated which regions of VapA were responsible for its effect on 
lysosomes. Surprisingly, it was found that the C-terminal core of VapA alone 
was sufficient to induce the swollen EL structures.  This was confirmed by the 
fact that a VapA N-terminus/ VapD core chimeric protein had no effect on 
lysosome morphology. Our data strongly suggest that the activity of VapA can 
be attributed to the core barrel structure alone. The structure of the Vap 
proteins has no obvious ligand binding sites or grooves and gives no hints as 
to its function. As only late endocytic compartments appear to be affected it is 
tempting to speculate that VapA requires a decrease in pH or needs to be 
proteolytically processed to become active. Alternatively, VapA may interact 
with a host-cell component only found within the lumen of late endocytic 
compartments. 
 
Together our data provide the first evidence for a likely function for VapA, 
namely disruption of endolysosomes, and this is likely to be a key mechanism 
for intracellular survival of R. equi. Despite the high degree of sequence 
homology between the Vap proteins, only VapA can disrupt the function of 
lysosomes.  Further analysis of the differences in the C-terminal core of VapA 
compared to other Vap proteins should be a fruitful future route towards 
discovering the precise mechanism of action of this virulence protein.  
 
 
Experimental Procedures 
Reagents. Mouse anti-rat LGP120 (GM10) and anti-rat LGP110 were 
generous gifts from Prof. Paul Luzio (University of Cambridge).  Rabbit anti-
VapA was a kind gift from Prof. A. Haas (University of Bonn). Mouse anti-myc 
antibody (9E10), rat anti-mouse LAMP1 (1D4B) and mouse anti-human 
LAMP1 (H4A3) were from the Developmental Studies Hybridoma Bank 
(DSHB, University of Iowa). ciMPR antibodies (ab124767) were from Abcam. 
Rabbit monoclonal antibodies to Rab5 (C8B1) and Rab7 (D95F2) were from 
Cell Signaling Technology. Anti-LC3 (clone 5F10) was from Nanotools, anti-
LBPA (clone 6C4) was from Merck Millipore. The plasmid for producing 
recombinant VapAD was a kind gift from Wim Meijer (University College 
Dublin). All chemical reagents and the mouse monoclonal anti-α-tubulin were 
from Sigma. 
Mammalian cell culture. All cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10 % (v/v) FBS, 2 mM glutamine and 1 
% (v/v) penicillin-streptomycin (10 U/ml and 10 µg/ml respectively) in a 
humidified 5 % CO2 atmosphere at 37 ºC, unless otherwise stated. Flp-In 
HeLa cells were a kind gift from Prof. M. Lowe (University of Manchester) and 
an isogenic cell line expressing myc-VapA was made by cloning myc-VapA 
into pCDNA5/FRT/TO and transfecting cells with this vector along with 
pOG44. Transfected Flp-In HeLa cells were selected with 50 µg/ml 
Hygromycin B (Roche) and protein expression was induced with 1 µg/ml 
doxycycline for 24h. 
Recombinant protein production. E.coli (B21 DE3 pLysS) were transformed 
with plasmids encoding either GST- or His6-tagged proteins as appropriate. 
Bacteria were grown in 2 x 600 ml of LB or 2TY broth as follows: 7.5 ml of LB 
(plus the appropriate selective antibiotics) was inoculated with a single 
bacterial colony and grown overnight at 37 ºC with shaking. The next day, 
starter cultures were diluted 1:500 into a total volume of 600 ml LB or 2TY 
broth, and grown at 37 ºC until an OD600 of 0.6 - 2.0 was obtained. Protein 
production was induced with IPTG to a final concentration of 0.2 mM, and 
cultures grown for a further 4 h. The bacteria were pelleted at 2,645 x g for 15 
min at 4 ºC. The cell pellet was resuspended in 10 ml of bacterial lysis buffer 
(1 % (v/v) Triton X-100, 1 mg/ml lysozyme, 2 mM MgCl2, 1 U/ml DNAse, in 
PBS) with protease inhibitors (Roche), and frozen at -20 ºC overnight. The cell 
pellet was defrosted on ice and centrifuged at 47,800 x g in a Sorvall SS34 
rotor for 20 min at 4 ºC. For GST fusion proteins, the supernatant was 
incubated with 1 ml (packed volume) of glutathione sepharose (GE 
healthcare) for 1 h at 4 ºC with gentle rotation. The sepharose beads were 
then collected and washed with 3 x 20 ml of wash buffer (1 % (v/v) Triton X-
100 in PBS). GST/GST-fusion proteins were eluted with 20 ml elution buffer 
(50 mM Tris, pH 8.0, 10 mM reduced glutathione). These fractions were then 
analysed by SDS-PAGE. The eluted proteins were then pooled and dialysed 
extensively into PBS at 4 ºC for 2 days and stored at -20 ºC until needed. For 
the purification of His6-tagged proteins, cell pellets were processed as above. 
The soluble supernatant was incubated with 134 µl (packed volume) of His-
Select resin (Sigma) for 1-2 h at 4 ºC with gentle rotation. The beads were 
washed with 3 x 20 ml wash buffer (10 mM imidazole, 0.3 M NaCl, 50 mM 
Na2HPO4, pH8.0). Proteins were eluted with 20 ml elution buffer (250 mM 
imidazole, 0.3 M NaCl, 50 mM Na2HPO4, pH 8.0) and 1 ml fractions collected. 
Fractions were analysed by SDS-PAGE. The eluted proteins were then 
pooled and dialysed extensively into PBS at 4 ºC for 2 days and stored at -20 
ºC until needed.  
Cell feeding experiments. J774.2, NRK or HeLa cells were seeded onto glass 
coverslips in 24 well plates and cultured for 24 h. Cells were then incubated 
with the appropriate protein at 100 µg/ml for varying amounts of time. Cells 
were routinely rinsed three times with PBS and then fixed and processed for 
confocal microscopy as described. Where cells were fed VapA in the 
presence of Bafilomycin-A1, the Bafilomycin-A1 concentration was 100nM. 
LysoTracker and MagicRed Cathepsin-B substrate experiments. For 
LysoTracker experiments, NRK cells stably expressing LGP120-GFP (a kind 
gift from J. P. Luzio, University of Cambridge) were seeded onto glass 
bottomed 35mm dishes (MatTek Corporation) before being incubated with 
100 µg/ml of recombinant VapA-His6 or VapD-His6  protein for 24h. The cells 
were then incubated with LysoTracker (as per the manufacturer’s instructions) 
for 5 min before the LysoTracker and LGP120 were visualised on a Zeiss 880 
confocal microscope. For Magic Red Cathepsin-B substrate (ABD Serotec 
Ltd) experiments, cells seeded onto glass bottomed dishes were incubated 
with or without VapA for 24 h before the medium was exchanged for medium 
containing the Magic Red cathepsin-B substrate (as per the manufacturer’s 
instructions). Ten minutes after the addition of the substrate the cresyl violet 
fluorphore was visualized on a Zeiss 880 confocal microscope using the 
561nm laser line at 2% power. For FRAP experiments, 10 images were taken 
before regions of interest were bleached using 50 iterations with combined 
laser lines 488nm at 4% power, 514nm at 2% power, 561nm at 100% power 
and 633nm at 0.2% power and then up to 300 images were subsequently 
taken with the 561nm laser line at 2% power. 
R. equi infection. NRK and J774.2 cells were seeded onto glass coverslips 
and cultured for 48 h in antibiotic-free DMEM medium supplemented with 10 
% (v/v) FBS (heat inactivated to 56 ºC for 30 min) and 2 mM glutamine. R. 
equi was cultured overnight in BHI media with shaking at 30 ºC. Bacteria were 
surface labeled with Alexa Fluor-488 as described ((Fernandez-Mora et al., 
2005). An appropriate number of bacteria were taken to infect mammalian 
cells at an MOI (multiplicity of infection) of 10 and resuspended in PBS. 
Bacteria were centrifuged onto cells at 80 x g for 5 min and incubated for 1 h 
at 37 ºC to allow phagocytosis of bacteria. Monolayers were rinsed 3 times 
with DMEM to remove unbound bacteria, and the media replaced with DMEM 
containing 150 µg/ml gentamycin to kill extracellular bacteria. The cells were 
cultured for a further hour, and washed with PBS. The media was then 
replaced with DMEM containing 10 µg/ml gentamycin, and cells cultured for 
24 h to allow intracellular bacteria to grow. Cells were fixed with 4 % 
formaldehyde in PBS for 20 min at room temperature and then processed for 
immunofluorescence.  
Western blotting. Proteins were transferred to nitrocellulose membranes using 
the iBlot system (Invitrogen) as per the manufacturer’s instructions. 
Membranes were then blocked in either 5 % (w/v) semi-skimmed milk or 5 % 
(w/v) BSA in TBS (100 mM NaCl, 10 mM Tris-HCl, pH 7.4) + 0.1 % (v/v) 
Tween-20 (TBST) for 30 min at room temperature or overnight at 4 oC. 
Membranes were probed with primary antibodies in 5 % (w/v) milk or 5 % 
(w/v) BSA TBST for 1 h at room temperature or 4 oC overnight. Membranes 
were then washed with TBST (3 x 5 minute washes) and incubated with 
horseradish peroxidase conjugated secondary antibodies in milk or BSA at 
room temperature for 30 min. Membranes were washed a further 3 times with 
TBST and then proteins were visualised using ECL reagent (GE Healthcare). 
Immunofluorescence. Cells were rinsed once with Dulbecco’s PBS (Sigma) 
and then fixed with 4 % formaldehyde in PBS for 20 min at 20ºC before 
quenching in 50 mM NH4Cl in PBS for 10 min. For the LC3 antibody cells 
were further fixed for 10 min with -20ºC MeOH at -20ºC. After fixation, cells 
were permeabilised in 0.2 % (w/v) BSA, 0.05 % (w/v) Saponin in PBS, for 10 
min. All further washes and antibody dilutions were carried out in 
BSA/Saponin/PBS (BSP) solution. In all cases, coverslips were incubated with 
primary antibodies diluted in BSP for 1 h at room temperature. Coverslips 
were washed 3 x 5 min with approximately BSP and then incubated with 
Alexa fluorophore-conjugated secondary antibodies (diluted 1:300 in BSP) for 
30 min, followed by a further 3 x 5 min washes with BSP. For visualisation of 
DNA 4',6-diamidino-2-phenylindole (DAPI) was included at 1 µg/ml in the final 
wash. Coverslips were rinsed once in distilled water, blotted dry, and mounted 
onto slides with MOVIOL 4-88 containing 2.5 % (w/v) DABCO (1,4-
diazobicyclo [2,2,2]-octane). Slides were viewed on a Zeiss LSM 880 inverted 
confocal laser microscope running Zen software (2015) or a Zeiss LSM 510 
meta Axioplan 2M upright confocal laser microscope running Zen software 
(2009, Carl Zeiss Ltd, Germany). Gain and laser powers were set accordingly. 
All images are maximum-intensity z projections unless otherwise stated. The 
size of puncta were determined using ImageJ and setting threshold levels to 
match the fluorescence, setting the scale for the image being analysed and 
then using the default analyze particles option. 
Electron microscopy. 10nm BSA-gold was made as previously described 
(Bright et al., 1997). Cells were pulsed for 4h with BSA-gold, washed with 
PBS and the gold chased for 4h before feeding cells VapA for 24h. Cells were 
then fixed with 0.1M Na cacodylate, pH 7.2, 2% (w/v) PFA and 2.5% (w/v) 
glutaraldehyde for 1h at 20ºC. Cells were scraped and pelleted at 16,500g for 
10 min. Cells were post fixed with 1% (w/v) OsO4 in 0.1 M sodium cacodylate 
buffer, pH 7.2, ‘en bloc’ stained with 0.5% (w/v) uranyl acetate in 50 mM 
sodium maleate buffer, pH 5.2, dehydrated in ethanol and processed for TEM 
in Araldite CY212 epoxy resin (Agar Scientific, Stansted, United 
Kingdom).   Ultrathin sections (50 nm) were mounted on formvar/carbon-
coated EM grids and stained with uranyl acetate and lead citrate.  Sections 
were examined with an FEI Tecnai G2 Spirit BioTwin transmission electron 
microscope (Eindhoven, The Netherlands) at an operating voltage of 80 kV 
and images were recorded with an Eagle 4K CCD camera. 
Cellular fractionation. NRK cells were scraped into STM buffer (250 mM 
sucrose, 10mM TES, pH 7.2, 1mM MgCl2 and then subjected to nitrogen 
cavitation (Parr Instrument Company) at 500psi for 10 min. 1ml of STM buffer 
was used for every confluent T75 flask. The lysates were centrifuged at 
1,500g for 10 min and 600µl of the post nuclear superntatant overlayed onto 
Nycodenz gradients consisting of 2ml 10% (w/v) Nycodenz, 2ml 16% (w/v) 
Nycodenz and 0.5ml 45% (w/v) Nycodenz. Nycodenz solutions were made by 
diluting 60% (w/v) Nycodenz with STM buffer. Gradients were centrifuged in a 
Beckman VTi90 rotor at 90,000rpm for 1h. Gradients were pumped off from 
the bottom using a long needle and a peristaltic pump, collecting 
approximately 27 x 190µl fractions. ß-hexosaminidase was assayed as 
previously described (Pryor, 2016). 
TFEB experiments. A TFEB-GFP construct in a pEGFP vector was a gift from 
Andrea Ballabio (Telethon Institute of Genetics and Medicine, Pozzuoli, NA, 
Italy) and was subcloned into a pLXIN retroviral expression vector (Clontech, 
Mountain View, CA, USA). A clonal NRK cell line stably expressing TFEB-
GFP was generated using the pLXIN retroviral system as previously 
described (Gordon et al 2009). Transduced cells of mixed expression levels 
were selected by culture in medium supplemented with 0.5 mg/ml Geneticin 
(G418) and clonal NRK cell lines expressing TFEB-GFP were subsequently 
generated after isolating single cells by fluorescence activated cell sorting. 
Nuclear translocation of TFEB-GFP was quantified after fixing with 4% (w/v) 
paraformaldehyde and staining nuclei with Hoechst 33342 using a Cellomics 
ArrayScanTM VTi high content screening, wide-field microscope with Cellomics 
ArrayScanTM software. After autofocussing using the Hoechst 33342 channel 
to detect the nuclei, the programme maps and outlines the area of each 
nucleus (Nuc) and a region extending outwards by an adjustable number of 
pixels (Cyt, representing a significant portion of the cytoplasm).  Nuclear 
translocation is calculated as the NucCyt difference (AU, arbitrary units), 
which is mean fluorescence intensity in Nuc after subtracting the mean 
intensity of pixels in Cyt. (Mean ± SEM of 750 cells). Treatment with Torin 1 
(250nM for 90min) was used as a positive control for TFEB-GFP translocation 
to the nucleus (Settembre et al., 2012). Images showing TFEB-GFP 
localization were obtained from paraformaldehyde-fixed cells using a Zeiss 
LSM 880 confocal microscope. 
 
 
 
  
Figure 1. VapA expression in the cytoplasm of cells has no effect on 
endocytic compartments. 1 µg/ml doxycycline was added to HeLa cells to 
induce expression of myc-VapA for 24 h. Cells were fixed and double labelled 
with myc and EEA1 (A), ciMPR (B) and LAMP1 (C) antibodies followed by 
fluorescently labelled secondary antibodies. Myc labelling is shown in red and 
organelle labelling is shown in green. Scale bars 20 µm.  
Figure 2. VapA induces lysosomal swelling from within the lumen of 
lysosomes. A. HeLa cells were incubated with or without 100 µg/ml 
recombinant VapA-His6 protein in the cell medium for 24 h. Cells were then 
fixed and double immunolabelled with	   α-VapA antibodies and α-LAMP1 
antibodies followed by fluorescently labelled secondary antibodies. VapA 
labelling is shown in red and LAMP1 labelling is shown in green. B. J774.2 or 
NRK cells were incubated with or without 100 µg/ml recombinant GST-VapA 
or recombinant VapA-His6 proteins for 24h, respectively. Cells were then fixed 
and labelled with α-LAMP1 (J774.2) or α-LGP120 (NRK) antibodies followed 
by fluorescently labelled secondary antibodies. Scale bar 10 µm C. NRK cells 
were incubated with 100 µg/ml recombinant GST protein or 1 µg/ml LPS for 
24 h. Cells were then fixed and labelled with α-LGP120 antibodies followed by 
fluorescently labelled secondary antibodies (green). Cell nuclei were stained 
with DAPI (blue). Scale bar 20 µm. All images are confocal maximum intensity 
z-projections. Wider fields of view are shown by figure S2. D. Quantification of 
the number of HeLa cells showing swollen lysosomes Data are from a typical 
experiment. Numbers in parentheses represent the number of cells that were 
scored. E. Quantification of lysosomal size in HeLa, J774.2 and NRK cells in 
control cells (open bars) and cells fed VapA (closed bars). Data are from a 
typical experiment. Numbers in parentheses represent the number of 
lysosomes that were counted (approximately 60 cells per condition). 
Figure 3. R. equi infected NRK cells show swollen lysosomal  
compartments. A. J774.2 were seeded onto glass coverslips and cultured for 
48 h in antibiotic-free DMEM medium. Cells were then infected with Alexa 
Fluor-488 surface-labelled R. equi (green) with an MOI of 10 and cells 
cultured for 24 h to allow intracellular bacteria to grow. Cells were fixed and 
immunolabelled for LAMP1 followed by a fluorescently labelled secondary 
antibody (red). Cell nuclei and bacterial DNA were stained with DAPI (blue). 
Scale bars 10 µm. Images are confocal maximum intensity z- projections. B. 
NRK cells were infected as for J774.2 cells but lysosomes were 
immunolabelled with an antibody against LGP120. A region is highlighted 
which is magnified (bottom panels). Scale bar 10µm. Scale bar for the 
magnified image is 2µm. Images were acquired using a Zeiss LSM 880 with 
Airyscan processing and shown with a maximum intensity z-projection. 
Figure 4. The core of VapA is sufficient to cause lysosomal swelling. A. 
Alignment of the sequences of VapA, VapD and VapG displayed together with 
the secondary structure elements of VapD using the programme ESPRIPT 
(Robert et al., 2014). Invariant residues in the alignment are shown in white 
type on a red background; conserved residues are in blue boxes. B. Ribbon 
representation of the structures of VapD and VapG with the secondary 
structure elements labelled. In each case the ribbon is colour-ramped from the 
N-terminus (blue) to the C-terminus (red). C. NRK cells were incubated with 
100 µg/ml of recombinant VapA, VapD or VapG for 24 h. Cells were then fixed 
and immunolabelled with LGP120 antibodies followed by Alexa Fluor-488- 
labeled anti-mouse secondary antibodies (green). Cell nuclei were stained 
with DAPI (blue). Images are representative of three separate experiments. D. 
Schematic representation of recombinant chimeric Vap proteins used in cell-
feeding experiments as shown by panel C. Residue numbers correspond to 
the full protein sequence including the signal peptide. N-term refers to the 
unstructured N-terminal region and C-terminal core represents the β-barrel 
‘core’ structure.  E. NRK cells were incubated with 100 µg/ml of recombinant 
VapA core, VapDA or VapAD for 24 h. Cells were then fixed and double 
immunolabelled with LGP120 and ciMPR antibodies followed by fluorescently 
labelled secondary antibodies. Images are representative of two separate 
experiments. Scale bars 10 µm. All images are confocal maximum intensity z-
projections. Wider fields of views of immunofluorescence images are shown 
by figure S4. 
Figure 5. VapA feeding to cells induces the formation of large 
endolysosomes. A. Cells were pulse-chased with 10nm BSA-gold before 
feeding cells with or without 100 µg/ml VapA protein for 24h. Cells were fixed 
and processed for electron microscopy. Electron micrographs show the 
flocculated BSA-gold in control and VapA treated cells. Scale bars = 500nm. 
B. NRK cells (treated with or without VapA protein for up to 48h) were lysed 
using nitrogen cavitation and the lysates subjected to fractionation on a 10%-
16% Nycodenz gradient. Fractions were taken from the bottom of the gradient 
and analysed for ß-hexosaminidase activity. C. Gradient fractions (as in B) 
were western blotted for the late endosomal marker ciMPR. D-H. NRK cells 
were incubated with or without 100µg/ml recombinant VapA-His6 for 24h. 
Cells were then fixed and labelled with fillipin and LGP120 (D), LBPA and 
LGP110 (E), Rab5 and LGP120 (F), Rab7 and LGP120 (G) and LC3 and 
LGP110 (H). Antibodies were visualized by labeling with fluorescently labeled 
secondary antibodies. Scale bars 10 µm. All images represent maximum 
intensity z-projections. The images in H were taken using a Zeiss 880 
confocal microscope and had additional Airyscan processing. The right hand 
panels of H are magnifications of the indicated regions of the merge panels. I 
Western blotting of lysates for α-tubulin and LC3 of cells treated with or 
without 100µg/ml VapA-His6 or 100µg/ml VapA-His6 and 100nM Bafilomycin-
A1 for 24h. 
Figure 6. Cells fed VapA have reduced cathepsin-B activity. A. NRK cells 
stably expressing LGP120-GFP (a kind gift from J. P. Luzio, University of 
Cambridge) were incubated with 100 µg/ml of recombinant VapA-His6 or 
VapD-His6  protein for 24h. The cells were then incubated with LysoTracker for 
5 min before the LysoTracker and LGP120 were visualised on a Zeiss 880 
confocal microscope. Acidic compartments are shown by red and lysosomes 
by green. Scale bars are 20µm. Quantification of co-localisation is shown by 
Pearson-Spearman correlations and scatterplots as described (French et al., 
2008). B. NRK cells were incubated with or without 100 µg/ml recombinant 
VapA or VapD protein for 24 h. Cells were then incubated with Cathepsin B 
MagicRed substrate for 10 min before imaging the site of active cathepsin B 
using an Andor Revolution XD spinning disk microscope. Scale bars 10 µm. 
C. Representative images of Magic-Red Cathepsin-B substrate in control cells 
and cells fed 100 µg/ml of recombinant VapA for 24h before and after 
photobleaching. The photobleaching ROI is shown by boxed areas. Timings 
are in seconds after the start of image acquisition. D. Quantification of FRAP 
data as seen in C. Data are the means ± SEM from 7-9 cells for each 
condition. 
Figure 7. VapA induces lysosome biogenesis. A. NRK cells were 
incubated with 100 µg/ml of recombinant VapA for the times indicated. Cells 
were then fixed and immunolabelled with LGP120 antibodies followed by 
fluorescently labelled secondary antibodies. Images are representative of 
three separate experiments. Scale bar 10 µm. B. NRK cells were incubated 
with 100 µg/ml of recombinant VapA-His6, VapD-His6 or VapG-His6 for the 
times indicated. Cell lysates were then western blotted for lysosomes 
(LGP120), late endosomes (ciMPR) and the cytoskeleton (α-tubulin). 20 µg of 
protein was loaded per lane. The blots are representative of three separate 
experiments. C. NRK cells expressing TFEB-GFP were incubated with 100 
µg/ml recombinant VapA for the times indicated, or with 250 nM Torin 1 for 90 
min (positive control). The cells were then fixed and labelled with α-LGP120 
antibodies followed by fluorescently labelled secondary antibodies. Scale bar 
10 µm. D. NRK cells expressing TFEB-GFP were incubated with increasing 
concentrations of VapA, VapD or VapG for 24 h. The cells were rinsed with 
PBS then fixed. Cell nuclei were stained with Hoechst 33342 dye for 10 min. 
The cells were then scanned on a Cellomics Arrayscan plate reader to 
measure the translocation of TFEB-GFP from the cytoplasm to the nucleus as 
described. Data is plotted as a difference of the fluorescence intensity in the 
nucleus compared to the cytoplasm. E.  NRK cells expressing TFEB-GFP 
were incubated with 100 µg/ml of recombinant VapA, VapD or VapG for the 
times indicated. The translocation of TFEB-GFP into the nucleus was 
measured as in D. Data are means ± SEM (n=1, >800 cells per condition). 
Figure 8. Model of VapA action on the late endocytic pathway. A. In 
normal cells late endosomes and/or autophagosomes fuse with lysosomes to 
form an endolysosome (EL) or an autolysosome (AL). The material delivered 
to the lysosome is then digested and the lysosome re-forms from the EL/AL 
compartment. B. VapA reduces the hydrolase activity in the EL/AL and 
material delivered to the lysosome accumulates. Lysosomes cannot be re-
formed from the perturbed EL/AL causing a loss of lysosomes. The lack of 
functional lysosomes is sensed by the cell and TFEB signaling promotes 
lysosome biogenesis to compensate. 
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 Supplemental figure legends 
Figure S1. Feeding HeLa cells recombinant VapA causes swelling of late 
endosomes but not early endosomes. A. HeLa cells were incubated with or 
without 100 µg/ml VapA-His6 for 24 h. Cells were then fixed and labelled with 
anti-ciMPR and anti-VapA antibodies followed by fluorescently labelled 
secondary antibodies. Scale bar 20 µm. All images are confocal maximum 
intensity z-projections. B. NRK cells were incubated with or without 100 µg/ml 
VapA-His6 for 24 h. Cells were then fixed and labelled with EEA1 and LGP120 
antibodies followed by fluorescently labelled secondary antibodies. Scale bar 
20 µm. All images are confocal maximum intensity z-projections.  
Figure S2. VapA induces lysosomal swelling in a variety of cell types. A. 
Immunofluorescence staining of lysosomes in cells (HeLa, J774.2 and NRK) 
treated with or without VapA (as figure 2). Images are single confocal slices. 
Scale bars 10µm. B. Immunofluorescence staining of lysosomes in NRK cells 
fed GST or LPS (as figure 2). Single confocal slice. Scale bars 10µm. 
Figure S3. J774.2 and NRK cell infection with R.equi. A. Control J774.2 
cells (top panels) immunoabelled for LAMP1 (red) and nucleic acid stained 
with DAPI (blue). Bottom panels show cells infected with Alexa Fluor-488-
labelled R. equi. Scale bars 10µm. B As J774.2 cells in A but using NRK cells 
and labeling lysosomes with an antibody raised against LGP120 (red). 
Bacteria are shown by closed arrowheads. Scale bars 10µm. C Typical 
infection rates of NRK and J774.2 cells with R. equi at a MOI of 10. Numbers 
in parentheses represent the number of cells analysed. n=1 
Figure S4. Determining the regions of VapA required for lysosomal 
swelling. A. Immunofluorescence of NRK lysosomes in cells treated with 
VapA, VapD and VapG (as figure 4C). Scale bars 10µm. B. NRK cells were 
incubated with 100 µg/ml of recombinant VapA core, VapDA or VapAD for 24 
h. Immunofluorescence shows the LGP120 (as figure 4E). Scale bars 10µm. 
Figure S5. Localisation of endocytic markers in cells treated with VapA. 
Immunofluorescence in NRK cells of LBPA, Rab 5, Rab7 and LC3 and 
lysosomes (LGP120 or LGP110) in cells treated with or without VapA. Colour 
of the text indicates the colour of the protein. Quantification of the degree of 
colocalisation of the two fluorphores of the images shown. p= Pearson’s 
correlation coefficient, s= Spearman’s correlation coefficient (French et al., 
2008). Scale bars 10µm. 
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